<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03204734</url>
  </required_header>
  <id_info>
    <org_study_id>ZJCH15009</org_study_id>
    <nct_id>NCT03204734</nct_id>
  </id_info>
  <brief_title>Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen at Least 2nd Line in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer</brief_title>
  <official_title>Evaluate Effectiveness and Security of Capecitabine or Endocrinotherapy as a Maintenance Therapy Regimen After 2nd-line or Over 2nd-line Therapy With Capecitabine Combine Regimen in Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A single-site study about the efficacy of sequential monotherapy: Capecitabine vs. endocrine
      therapy, in metastatic breast cancer patients with HR-positive &amp; HER2-negative after
      capecitabine-base chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Capecitabine-base chemotherapy must be ≥Second-line Therapy
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2016</start_date>
  <completion_date type="Anticipated">December 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>Progression-free survival (PFS) is defined as the time elapsed between enrolling and tumor progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical benefit rate(CBR)</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>the response is CR+PR+SD ≥ 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of enrolling until the date of death from any cause, assessed up to 3 years</time_frame>
    <description>the time elapsed between enrolling and death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Grade 3/4 adverse events</measure>
    <time_frame>From date of enrolling until the date of 1 month of stop treatment, assessed up to 3 years</time_frame>
    <description>Number of Participants with Grade 3/4 Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QOL)（1）</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>change from enrolling to progression disease or death according EORTC QLQ-C30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life(QOL)（2）</measure>
    <time_frame>From date of enrolling until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years</time_frame>
    <description>change from enrolling to progression disease or death according EORTC BR23</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capecitabine by mouth twice per day for 14 days, per 21 days as a cycle, until disease progress or toxicity can not be tolerated.Capecitabine starting dose was the dose used at the end of the combined chemotherapy regimen,eg:1000mg per BSA.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>endocrine therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>endocrine therapy will been given as a sequential treatment in Metastatic breast cancer patients who are got benefit in capecitabine-base chemotherapy.The medicine will be confirmed by the patient's past-treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.</description>
    <arm_group_label>Capecitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>endocrine therapy</intervention_name>
    <description>endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.</description>
    <arm_group_label>endocrine therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  The age is Above 18 years of age, &lt;70 years old

          -  HR-positive &amp; HER2-negative

          -  Metastatic breast cancer,incurable.

          -  For recurrent or metastatic lesions has had at least 1 but no more than 3 kinds of
             chemotherapy, if there is disease progression within 6 months after the end of the
             adjuvant chemotherapy, adjuvant chemotherapy will been the first-line treatment for
             metastatic lesions

          -  No prior use of capecitabine therapy or the use of capecitabine treatment was
             effective, and the efficacy evaluation was CR/PR/SD more than 6 months.

          -  Eastern Cooperative Oncology Group performance status (ECOG PS)=0~1

          -  The basic function of normal bone marrow

          -  Functions of liver and kidney is normal

          -  Expectation of life is more than 3 months

          -  Agreed to take contraceptive measures during treatment

        Exclusion Criteria:

          -  Previous toxicity was not recovered to 0-1 degrees

          -  Central nervous system metastasis

          -  Pregnancy or lactation

          -  There are uncontrolled infection, myocardial infarction, thrombosis, etc.

          -  There are uncontrolled chronic diseases such as diabetes, hypertension, peptic ulcer,
             chronic hepatitis, mental disease;

          -  Researchers believe that is not suitable for the study

          -  Patients with other malignant tumor history, except the healed skin basal cell
             carcinoma and carcinoma of uterine cervix;

          -  Bilateral breast cancer

          -  Capecitabine was ineffective in past treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xiao-jia Wang, PHD,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhejiang Cance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiao-jia Wang, PHD,MD</last_name>
    <phone>86 13906500190</phone>
    <email>wxiaojia0803@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ya-bing Zheng, MD</last_name>
    <phone>13858065353</phone>
    <email>zhengyabing@sina.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaojia WANG, MD,PhD</last_name>
      <phone>+86 13906500190</phone>
      <email>wxiaojia0803@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Ya-bing Zheng, MD</last_name>
      <phone>+8613858065353</phone>
      <email>zhengyabing@sina.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Muss HB, Case LD, Richards F 2nd, White DR, Cooper MR, Cruz JM, Powell BL, Spurr CL, Capizzi RL. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med. 1991 Nov 7;325(19):1342-8.</citation>
    <PMID>1922236</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2017</study_first_submitted>
  <study_first_submitted_qc>June 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <last_update_submitted>June 27, 2017</last_update_submitted>
  <last_update_submitted_qc>June 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Zhengyabing</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>therapy</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

